Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch

On Wednesday, Eli Lilly Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Benzinga

Abandoning daylight saving time could prevent over 300,000 stroke cases a year in the US, study claims

Springing forward by an hour each March knocks the circadian rhythm out of alignment. A new model of the chronic health impacts argues for scrapping it entirely.

LiveScience

Roche Targets Top Spot In Weight Loss Drug Market

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes competition with Eli Lilly And Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Metsera Stock Rockets After Pfizer's $7.3b — Should You Still Invest?

Metsera stock has soared after Pfizer announced a $7.3 billion acquisition, sparking investor buzz. Analysts are now weighing whether the biotech rally has more room to run or if buyers should stay cautious.

International Business Times UK

Pfizer eyes obesity drug market as it seals $4.9bn deal for Metsera

Pharma giant Pfizer is betting on obesity treatments as it looks for new markets following the success of its COVID-19 vaccine.

Euronews

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

Benzinga

Pfizer amps up push into obesity treatments with $4.9B deal for Metsera

Pfizer is doubling down on obesity treatments by spending $4.9 billion on the development-stage drugmaker Metsera

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market

Pfizer Inc. (NYSE:PFE) stock climbed 1.54% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ:MTSR), a developer of anti-obesity drugs.

Benzinga

Could This New Drug Be The Safer Way To Fight Obesity?

On Friday, Skye Bioscience, Inc. (NASDAQ:SKYE) announced the presentation of results from the Phase 1b study of nimacimab in subjects with metabolic-associated steatotic liver disease (MASLD) at the European Association for the Study of Diabetes (EASD) Annual Meeting.

Benzinga

Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything

Eli Lilly stock rises on FDA fast-track hopes for its oral GLP-1 obesity drug and $27B U.S. manufacturing expansion; it's a tough trade but solid long-term hold

MarketBeat

Novo Nordisk shares climb after positive anti-obesity pill results

Danish drugmaker jumps by about £9bn as trial shows ‘significant weight loss’ with tablet version of Wegovy

The Guardian - UK

New type of jab helps to maintain weight loss

Experts have developed a new drug which helps tackle the underlying causes of obesity.

The Independent UK

Vital breakthrough as once-a-day pill can help people lose ‘significant’ weight

A fifth of people taking the weight-loss tablet Orforglipron lost 20 per cent of their body weight

The Independent UK

Abolishing daylight saving time could slash these life-threatening health conditions

‘We found that staying in standard time or staying in daylight saving time is definitely better than switching twice a year’

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA takes aim at Hims and other telehealth services in drug advertising blitz

The Trump administration has issued its first warnings to online services that offer unofficial versions of popular drugs like the blockbuster obesity treatment Wegovy

Euronews

Doctors uncover genetic clues as to why obesity affects people differently

A large-scale study compared body fat levels with markers of metabolic health, such as blood pressure, cholesterol and blood sugar.

Euronews

Weight loss drugs like Ozempic work well for kids and teens, study finds. But should kids take them?

The Independent UK

Obese children as young as six could benefit from weight-loss jabs

About a third of children leaving primary school are overweight or living with obesity in England

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

How are overweight and obesity affecting EU citizens?

Overweight and obesity are rapidly increasing across Europe, a new study has found. In several Eastern European countries, three-quarters of men are overweight or obese.

The Guardian - US

Attack on obesity or cash grab? Tax hike on sugary drinks divides opinion in Mexico

Mexicans, who consume on average 166 litres of fizzy drinks a year, will face a near doubling of the tax rate

Evening Standard

A life-changing journey powered by wheels of cheese

There already exists a cure for ennui, and it’s found in the pub. But when former BBC producer and Canadian radio presenter Michael Finnerty — famous enough over there to have his face on billboards — finds his life without lustre, he does not turn to booze, which shows a…

The Guardian - UK

More than half of UK births now involve medical intervention, audit finds

Caesareans drive rise in assisted deliveries as experts warn of complex pregnancies linked to age, obesity and other conditions

Radio France Internationale

More of the world's children are obese than underweight, UN warns

For the first time, more school-aged children are obese than underweight around the world, with the exception of sub-Saharan Africa and South Asia. The warning came in a report released on Wednesday by the United Nations children’s agency Unicef.

Benzinga

Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets

The Institute for Clinical and Economic Review (ICER) on Tuesday released a Draft Evidence Report assessing the comparative clinical effectiveness and value of Novo Nordisk A/S’ (NYSE:NVO) semaglutide (Wegovy) and Eli Lilly and Co.’s (NYSE:LLY) tirzepatide (Zepbound) for obesity management.

Euronews

Novo Nordisk to cut 9,000 jobs as Eli Lilly competition intensifies

The pharmaceutical giant will axe over 11% of its global workforce as rival Eli Lilly gathers market share in the obesity drug market.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.